Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

28/05/2015
New online tool to predict genetic resistance to tuberculosis drugs

Finding out what drugs can be used to treat a patient with tuberculosis (TB) can be sped up by days or weeks, thanks to a new free online tool. The TB-Profiler tool , developed by a team of scientists led by Dr Taane Clark at the London School of Hygiene & Tropical Medicine, analyses and interprets genome sequence data to predict resistance to 11 drugs used for the...

Read more...





28/05/2015
68th World Health Assembly concludes in Geneva with key commitments by BRICS countries on TB

26 May 2015 - The 68th World Health Assembly, which gathered Ministers of Health from around the world to make key decisions on global health matters, concluded today in Geneva. The Stop TB Partnership met with Ministers of Health to advance key TB issues, organized side events, and ensured a strong voice for the TB community during the meeting. The Chair of the Stop TB Partnership...

Read more...





28/05/2015
Do sex and HIV/HCV coinfection affect response to antiretroviral treatment?

HIV-positive men and women coinfected with hepatitis C virus (HCV) showed impaired CD4 T-cell restoration after starting antiretroviral therapy (ART) and had a 40% greater risk of death than people with HIV alone, though they were equally likely to achieve HIV viral suppression, according to study findings published in the May 18 advance edition of AIDS Patient Care and STDs ....

Read more...





28/05/2015
HBV patients on long-term entecavir or tenofovir have low mortality, HCC still a risk

More than 95% of people with chronic hepatitis B were still alive after 5 years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread), and most deaths were due to non-liver-related causes, but hepatocellular carcinoma was still a major factor affecting mortality, researchers reported presented at the European Association for the Study of the Liver (EASL) 50th International...

Read more...





28/05/2015
Merck submits U.S. New Drug Application for grazoprevir/elbasvir, an investigational once-daily, single tablet combination therapy, for treatment of chronic hepatitis C genotypes 1, 4, and 6 infection

KENILWORTH, N.J., May 28, 2015--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for grazoprevir/elbasvir (100mg/50mg), an investigational once-daily, single tablet combination therapy for the treatment of adult patients with chronic hepatitis C genotypes...

Read more...

Source Source: Merck